Red queen therapeutics, INC - AOI#25(fastx) r & d for rapid response platform for the development of a pan-influenza virus fusion inhibitor for the treatment of influenza virus infections
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50124C00018
- Awardee
-
Red Queen Therapeutics Inc. UEI T4NRRVBPP5Z8
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $266,511
Award facts
- Opportunity
-
- BAA22100SOL00003 Solicitation number
- Contract value 100% obligated
- $266,511.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Basic Research
- Pricing
- Firm Fixed Price
- Place of performance
- Cambridge, MA 02142, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$483,488 | |
| Other Administrative Action | $0 | |
| Original award | $749,999 |
About this award
Red Queen Therapeutics Inc. was awarded a $266,511 firm fixed-price definitive contract by the Office of the Assistant Secretary for Preparedness and Response (ASPR) on May 10, 2024, for research and development activities supporting a rapid response platform designed to accelerate the development of a pan-influenza virus fusion inhibitor for treating influenza virus infections. The work is being performed in Cambridge, Massachusetts, with an ultimate completion date of July 9, 2025. This contract was awarded without a set-aside designation and represents ASPR's efforts to advance medical countermeasures and therapeutic capabilities in pandemic preparedness.
The engagement with Red Queen Therapeutics aligns with ASPR's mission to enhance the nation's preparedness for public health emergencies by supporting the development of broadly effective antiviral treatments. By funding early-stage research into fusion inhibitors that could address multiple influenza virus strains, this contract contributes to ASPR's strategic objective of reducing vulnerability to pandemic threats and ensuring the availability of effective therapeutic options for responding to influenza outbreaks and potential future viral threats.
Quick answers
Who was awarded contract 75A50124C00018?
75A50124C00018 was awarded to Red Queen Therapeutics Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on May 10, 2024.
How much is contract 75A50124C00018 worth?
The government has obligated $266,511 on 75A50124C00018.
Was contract 75A50124C00018 competed?
The extent of competition for 75A50124C00018 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award